Be sure to read Forbes’ story on Merck’s first-quarter earnings, which reporter Matthew Herper calls “a big disappointment”:
forbes.com/sites/matthewherp … ectations/
Also note this passage:
“Unfortunately, Januvia and other, similar drugs are currently being reviewed by the Food and Drug Administration to see if they increase the risk of a serious and painful condition called pancreatitis. There is no conclusion from this safety review, but if it is affecting overall demand it could seriously hurt Merck’s ability to grow sales. It doesn’t help that this echoes other problems in Merck’s past, including the withdrawal of Vioxx.”